Neutralising CCR5 in mouse models of melanoma leads to an increased survival time, reduced total numbers of MDSCs, and reduced immunosuppression by MDSCs, without diminishing the number of effector T cells infiltrating the tumour. This evidence concerns the gene CCR5 and melanoma.